Trial · NCT00882440
A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011)
NCT00882440, Phase 3, Completed, Merck Sharp & Dohme LLC; results first posted 2009-06-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011). Trials, record NCT00882440. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00882440
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011)
- NCT number
- NCT00882440
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 576 participants, actual
- Lead sponsor
- Merck Sharp & Dohme LLC
- Conditions
- Hypertension
- Interventions
- losartan potassium, Placebo, Enalapril
- First posted
- 2009-04-16
- Last updated
- 2015-08-27
- Results first posted
- 2009-06-10
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Change From Baseline in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8 | 24 hours post dose at Baseline and Week 8 | |
| Secondary | Categories of Antihypertensive Response in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8 | 24 hours post dose at Week 8 | Patients in Category I (defined as "excellent" in protocol) if SuDBP was \<90 mmHg, Category II (defined as "good" in protocol) if SuDBP was ≥90 but decreased at least 10 mmHg, or Category III (defined as "fair" or "inadequate" in protocol) if SuDBP was ≥90 and decreased less than 10 mmHg. |
| Secondary | Mean Change From Baseline in Peak Supine Diastolic Blood Pressure (SuDBP) at Week 8 | 6 hours post dose at Baseline and 8 weeks |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Categories of Antihypertensive Response in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8 | 24 hours post dose at Week 8 | An all patients treated approach was employed that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available. | Participants | NUMBER |
| PRIMARY | Mean Change From Baseline in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8 | 24 hours post dose at Baseline and Week 8 | The primary analysis employed an all patients treated approach that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available. | mm Hg | MEAN |
| SECONDARY | Mean Change From Baseline in Peak Supine Diastolic Blood Pressure (SuDBP) at Week 8 | 6 hours post dose at Baseline and 8 weeks | An all patients treated approach was employed that included patients with at least one treatment period measurement. The last measurements of withdrawn patients were carried forward to subsequent timepoints. Missing data were estimated by carrying forward data from the last visit (excluding baseline) at which it was available. | mm Hg | MEAN |
Source ClinicalTrials.gov
Results by group35
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Categories of Antihypertensive Response in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8 | Placebo | Category I | 10 | Participants | |
| Categories of Antihypertensive Response in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8 | Losartan 10 mg | Category I | 19 | Participants | |
| Categories of Antihypertensive Response in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8 | Losartan 25 mg | Category I | 21 | Participants | |
| Categories of Antihypertensive Response in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8 | Losartan 50 mg | Category I | 24 | Participants | |
| Categories of Antihypertensive Response in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8 | Losartan 100 mg | Category I | 29 | Participants | |
| Categories of Antihypertensive Response in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8 | Losartan 150 mg | Category I | 28 | Participants | |
| Categories of Antihypertensive Response in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8 | Enalapril 20 | Category I | 35 | Participants | |
| Categories of Antihypertensive Response in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8 | Placebo | Category II | 14 | Participants | |
| Categories of Antihypertensive Response in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8 | Losartan 10 mg | Category II | 17 | Participants | |
| Categories of Antihypertensive Response in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8 | Losartan 25 mg | Category II | 7 | Participants |
1 to 10 of 35Source ClinicalTrials.gov
See all 35 results by groupParticipant flow21
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 78 | |
| Overall Study | STARTED | Losartan 10 mg | 80 | |
| Overall Study | STARTED | Losartan 25 mg | 82 | |
| Overall Study | STARTED | Losartan 50 mg | 79 | |
| Overall Study | STARTED | Losartan 100 mg | 90 | |
| Overall Study | STARTED | Losartan 150 mg | 84 | |
| Overall Study | STARTED | Enalapril 20 | 83 | |
| Overall Study | COMPLETED | Placebo | 67 | |
| Overall Study | COMPLETED | Losartan 10 mg | 72 | |
| Overall Study | COMPLETED | Losartan 25 mg | 75 |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 7768585 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00882440
GET https://conductscience.org/api/trials/v1/NCT00882440/results?page=2